Intraocular activation of angiogenic and inflammatory pathways in uveal melanoma

Retina

Volumn 32, Issue 7, 2012, Pages 1373-1384

  Dunavoelgyi, Roman ^a   Funk, Marion ^a   Sacu, Stefan ^a   Georgopoulos, Michael ^a   Zlabinger, Gerhard ^b   Zehetmayer, Martin ^a   Schmidt Erfurth, Ursula ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

angiogenesis; cytokines; inflammation; intraocular; melanoma; uveal

Indexed keywords

EOTAXIN; FLT3 LIGAND; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR AA; RANTES; VASCULOTROPIN;

AGED; ANGIOGENESIS; AQUEOUS HUMOR; ARTICLE; BRUCH MEMBRANE; CARCINOGENESIS; CATARACT; CATARACT EXTRACTION; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PROSPECTIVE STUDY; UVEA MELANOMA; VITRECTOMY; VITREOUS BODY;

AGED; ANGIOGENESIS INDUCING AGENTS; AQUEOUS HUMOR; CHROMOSOMES, HUMAN, PAIR 3; CYTOKINES; EYE ENUCLEATION; FEMALE; HUMANS; MALE; MELANOMA; MONOSOMY; PROSPECTIVE STUDIES; UVEAL NEOPLASMS; VITREOUS BODY;

EID: 84862891315     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318239e299     Document Type: Article

References (43)

1. Egan KM, Seddon JM, Glynn RJ, et al. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 1988;32:239-251. (Pubitemid 18066234)
2. Bhat P, Jakobiec FA, Folberg R. Comparison of tumor-associated vasculatures in uveal and cutaneous melanomas. Semin Ophthalmol 2009;24:166-171.
3. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000;156:361-381. (Pubitemid 30648785)
4. Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vascu-logenic mimicry. Am J Pathol 1999;155:739-752. (Pubitemid 29426820)
5. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002;99:4283-4297. (Pubitemid 34627193)
6. Apte RN, Voronov E. Interleukin-1\-a major pleiotropic cytokine in tumor-host interactions. Semin Cancer Biol 2002; 12:277-290. (Pubitemid 35034572)
7. Becker C, Fantini MC, Wirtz S, et al. IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 2005;4: 217-220. (Pubitemid 41365319)
8. Berasain C, Castillo J, Perugorria MJ, et al. Inflammation and liver cancer: new molecular links. Ann N Y Acad Sci 2009; 1155:206-221.
9. Shimamura T, Fujisawa T, Husain SR, et al. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy. Clin Cancer Res 2010;16:577-586.
10. Boyd SR, Tan D, Bunce C, et al. Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. Br J Ophthalmol 2002;86:448-452. (Pubitemid 34293296)
11. Boyd SR, Tan DS, de Souza L, et al. Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth. Br J Ophthalmol 2002;86:440-447. (Pubitemid 34293295)
12. Ijland SA, Jager MJ, Heijdra BM, et al. Expression of angio-genic and immunosuppressive factors by uveal melanoma cell lines. Melanoma Res 1999;9:445-450. (Pubitemid 29494109)
13. Ly LV, Bronkhorst IH, van Beelen E, et al. Inflammatory cyto-kines in eyes with uveal melanoma and relation with macrophage infiltration. Invest Ophthalmol Vis Sci 2010;51:5445-5451.
14. Missotten GS, Notting IC, Schlingemann RO, et al. Vascular endothelial growth factor A in eyes with uveal melanoma. Arch Ophthalmol 2006;124:1428-1434. (Pubitemid 44537143)
15. Notting IC, Missotten GS, Sijmons B, et al. Angiogenic profile of uveal melanoma. Curr Eye Res 2006;31:775-785. (Pubitemid 44373549)
16. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995;1:1024-1028.
17. Funatsu H, Yamashita H, Nakamura S, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2006;113:294-301. (Pubitemid 43170779)
18. Funatsu H, Yamashita H, Sakata K, et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology 2005;112:806-816. (Pubitemid 40631499)
19. Funk M, Kriechbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 2009;50:1025-1032.
20. Noma H, Funatsu H, Mimura T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology 2009;116:87-93.
21. Noma H, Funatsu H, Mimura T, et al. Increase of vascular endothelial growth factor and interleukin-6 in the aqueous humour of patients with macular oedema and central retinal vein occlusion. Acta Ophthalmol 2010;88:646-651.
22. Patel JI, Tombran-Tink J, Hykin PG, et al. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with mac-ular edema: Implications for structural differences in macular profiles. Exp Eye Res 2006;82:798-806. (Pubitemid 43170880)
23. Pe'er J, Folberg R, Itin A, et al. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 1998;105:412-416. (Pubitemid 28125092)
24. Funk M, Schmidinger G, Maar N, et al. Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab. Retina 30:1412-1419.
25. Amin R, Puklin JE, Frank RN. Growth factor localization in choroidal neovascular membranes of age-related mac-ular degeneration. Invest Ophthalmol Vis Sci 1994;35: 3178-3188. (Pubitemid 24241356)
26. Frank RN. Growth factors in age-related macular degeneration: pathogenic and therapeutic implications. Ophthalmic Res 1997;29:341-353. (Pubitemid 27427367)
27. Jo N, Mailhos C, Ju M, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 2006;168: 2036-2053. (Pubitemid 43825322)
28. Stahl A, Paschek L, Martin G, et al. Combinatory inhibition of VEGF and FGF2 is superior to solitary VEGF inhibition in an in vitro model of RPE-induced angiogenesis. Graefes Arch Clin Exp Ophthalmol 2009;247:767-773.
29. Funk M, Karl D, Georgopoulos M, et al. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 2009;116:2393-2399.
30. Hurks HM, Metzelaar-Blok JA, Barthen ER, et al. Expression of epidermal growth factor receptor: risk factor in uveal melanoma. Invest Ophthalmol Vis Sci 2000;41:2023-2027. (Pubitemid 30450966)
31. Ma D, Niederkorn JY. Role of epidermal growth factor receptor in the metastasis of intraocular melanomas. Invest Ophthal-mol Vis Sci 1998;39:1067-1075. (Pubitemid 28247340)
32. Mallikarjuna K, Pushparaj V, Biswas J, Krishnakumar S. Expression of epidermal growth factor receptor, ezrin, hepato-cyte growth factor, and c-Met in uveal melanoma: an immu-nohistochemical study. Curr Eye Res 2007;32:281-290. (Pubitemid 46439685)
33. Scholes AG, Hagan S, Hiscott P, et al. Overexpression of epidermal growth factor receptor restricted to macrophages in uveal melanoma. Arch Ophthalmol 2001;119:373-377. (Pubitemid 32207259)
34. Cools-Lartigue J, Marshall JC, Caissie AL, et al. Secretion of interleukin-6 and prostaglandin E2 during uveal melanoma-monocyte in vitro interactions. Exp Eye Res 2004;79:451-454. (Pubitemid 39232115)
35. McLean IW, Saraiva VS, Burnier MN, Jr. Pathological and prognostic features of uveal melanomas. Can J Ophthalmol 2004;39:343-350. (Pubitemid 38886327)
36. Toivonen P, Makitie T, Kujala E, Kivela T. Microcirculation and tumor-infiltrating macrophages in choroidal and ciliary body melanoma and corresponding metastases. Invest Ophthal-mol Vis Sci 2004;45:1-6. (Pubitemid 38055660)
37. Melnikova VO, Bar-Eli M. Inflammation and melanoma metastasis. Pigment Cell Melanoma Res 2009;22:257-267.
38. Wu Y, Zhou BP. Inflammation: a driving force speeds cancer metastasis. Cell Cycle 2009;8:3267-3273.
39. Maat W, Ly LV, Jordanova ES, et al. Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Invest Ophthalmol Vis Sci 2008;49:505-510.
40. Esche C, Subbotin VM, Maliszewski C, et al. FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res 1998;58:380-383. (Pubitemid 28087392)
41. Song S, Liu C, Wang J, et al. Vaccination with combination of Fit3L and RANTES in a DNA prime-protein boost regimen elicits strong cell-mediated immunity and antitumor effect. Vaccine 2009;27:1111-1118.
42. Mattes J, Hulett M, Xie W, et al. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med 2003;197:387-393. (Pubitemid 36184245)
43. Wang LX, Li R, Yang G, et al. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lympho-depleted mice lead to tumor regression and editing. Cancer Res 2005;65:10569-10577. (Pubitemid 41743752)